What failed BIA 10–2474 Phase I clinical trial? Global speculations and recommendations for future Phase I trials

One of the major advances in this field was the generation of fatty acid amide hydrolase (FAAH) inhibitors.[3,4] FAAH hydrolyses the endocannabinoids with amide bonds including anandamide (AEA). Inhibition of FAAH would lead to extended endocannabinoid activity at its site of synthesis resulting in tissue selective activation of CB1 receptors. This enhanced endocannabinoid activity is suggested to be useful in the treatment of several clinical conditions. At present, a lot of research is being carried out to establish their role in the management of neuropathic pain.